3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
40
Sarcoma
8
Gynecologic
4
Gastrointestinal
4
Dermatologic
4
Thoracic
3
Genitourinary
3
Breast
3
Head & Neck
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
16
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hematologic Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Recurrence
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lymphoma, B-Cell
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Chronic-Phase
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Interventions
Paclitaxel
2
Azacitidine
2
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pembrolizumab
1
fludarabine
1
ceritinib
1
cc-486
1
carboxyamido-triazole
1
bemcentinib
1
acalabrutinib
1
abiraterone
1
Uncertainty
1
Thalidomide
1
Temozolomide
1
Sorafenib
1
Quality of Life
1
Psychosocial Intervention
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
O(6)-benzylguanine
1
Molecular Diagnostic Techniques
1
Leucovorin
1
Lenalidomide
1
Interleukin-2
1
Interleukin-15
1
Injections
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
pembrolizumab
×
Other hematologic neoplasm
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled